|
Volumn 277, Issue 2, 2002, Pages 1255-1260
|
MutS preferentially recognizes cisplatin-over oxaliplatin-modified DNA
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CELLS;
DNA;
ESCHERICHIA COLI;
PROTEINS;
TUMORS;
ANTICANCER DRUG;
BIOCHEMISTRY;
ADENOSINE DIPHOSPHATE;
CARRIER PROTEIN;
CISPLATIN;
CISPLATIN DERIVATIVE;
DIAMINOCYCLOHEXANE;
DNA;
LIGAND;
OXALIPLATIN;
PLATINUM DERIVATIVE;
UNCLASSIFIED DRUG;
ARTICLE;
BINDING AFFINITY;
CONTROLLED STUDY;
CYTOTOXICITY;
DESENSITIZATION;
DNA DAMAGE;
DNA MODIFICATION;
DRUG ACTIVITY;
DRUG DNA BINDING;
ESCHERICHIA COLI;
METHYLATION;
MISMATCH REPAIR;
MOLECULAR RECOGNITION;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN PROTEIN INTERACTION;
TUMOR RESISTANCE;
ADENOSINE TRIPHOSPHATASES;
ANTINEOPLASTIC AGENTS;
BACTERIAL PROTEINS;
BASE PAIR MISMATCH;
CELL SURVIVAL;
CISPLATIN;
DNA ADDUCTS;
DNA REPAIR;
DNA-BINDING PROTEINS;
ESCHERICHIA COLI;
ESCHERICHIA COLI PROTEINS;
MOLECULAR STRUCTURE;
MUTS DNA MISMATCH-BINDING PROTEIN;
ORGANOPLATINUM COMPOUNDS;
BACTERIA (MICROORGANISMS);
ESCHERICHIA COLI;
|
EID: 0037059778
PISSN: 00219258
EISSN: None
Source Type: Journal
DOI: 10.1074/jbc.M105382200 Document Type: Article |
Times cited : (93)
|
References (51)
|